Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CHI-202, CHI-101 · 1 trial · 1 indication
Blood pressure is measure by the combination of systolic and diastolic measurements
Respiratory rate will be measured as breaths per minute
Heart rate will be measured as heart beats per minute
Safety and tolerability will be assessed through Adverse Events and Serious Adverse Events
Safety and tolerability will be assessed through Adverse Events and Serious Adverse Events
Safety and tolerability will be assessed through Compliance with IP consumption (total # of self-reported doses consumed/maximum of 7 total possible doses consumed)
| Arm | Type | Description |
|---|---|---|
| Active | ACTIVE_COMPARATOR | CHI-202. Participants will drink one 7.0g CHI-202 powder sachet mixed into 16oz of water twice daily. |
| Placebo | PLACEBO_COMPARATOR | CHI-101. Participants will drink one 7.0g CHI-101 powder sachet mixed into 16oz of water twice daily. |
| Name | Type | Description |
|---|---|---|
| CHI-202 | DIETARY_SUPPLEMENT | Blend of cannabinoids \& other ingredients |
| CHI-101 | DIETARY_SUPPLEMENT | Placebo |
Inclusion Criteria: 1. Is a healthy adult aged 18-65 years, inclusive, at the time of screening. 2. Is exercise-trained, i.e., self-reports exercising at least 3 times per week for at least 30 minutes per session for the past year. 3. Has a body mass index between 18 and 35 kg/m2 (inclusive). 4. Is...
CHI-202 is an investigational drug being studied for Delayed Onset Muscle Soreness (DOMS), a condition of muscle pain and stiffness that occurs after intense physical activity. It is being developed as a potential treatment to support recovery from physical activity and is currently in Phase 2 clinical development.
CHI-202 is being developed by Canopy Growth Corporation, a company traded on the stock exchange under the ticker symbol CGC. The company is conducting clinical research on this investigational drug for the treatment of Delayed Onset Muscle Soreness (DOMS).
CHI-202 is in Phase 2 clinical development. A Phase 2 clinical trial has been completed to assess the safety, tolerability, and effects of CHI-202 for supporting recovery from physical activity in patients with Delayed Onset Muscle Soreness (DOMS).
CHI-202 has one completed clinical trial registered under NCT05026164, titled "Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity." This Phase 2 trial enrolled 40 participants with Delayed Onset Muscle Soreness (DOMS) and was not randomized, double-blind, or controlled.
CHI-202 and CHI-101 are both investigational drugs being developed by Canopy Growth Corporation, but they are distinct drug candidates. CHI-202 is being studied for Delayed Onset Muscle Soreness (DOMS), while CHI-101 is a separate compound with its own development program.